Intercos SpA (LTS:0AAR) reports a robust 12% EBITDA growth year-to-date, despite facing sales declines and market headwinds in Q3 2025.

Investing.com -- S&P Global Ratings has upgraded Pediatrix Medical Group Inc. to ’BB’ from ’BB-’ with a stable outlook, citing lower leverage and improved free operating cash flow (FOCF) expectations.